{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T19:02:11Z","timestamp":1779822131930,"version":"3.53.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","award":["Intramural faculty salary grant"],"award-info":[{"award-number":["Intramural faculty salary grant"]}],"id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","award":["Intramural faculty salary grant"],"award-info":[{"award-number":["Intramural faculty salary grant"]}],"id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"crossref","award":["OPP1192908"],"award-info":[{"award-number":["OPP1192908"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["2023-02396"],"award-info":[{"award-number":["2023-02396"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Seasonal vaccination is the most important strategy for mitigating the large disease burden caused by influenza virus. Licensed inactivated influenza virus vaccines rely on slow, egg-based production, underscoring the need for faster, more effective platforms that elicit robust immune responses. Here, we compare the immunogenicity of an unmodified mRNA-lipid nanoparticle vaccine encoding influenza hemagglutinin (HA) from A\/Michigan\/45\/2015 (H1N1)pdm09, A\/Singapore\/INFIMH-16-0019\/2016 (H3N2), B\/Phuket\/3073\/2013 and B\/Colorado\/06\/2017 with two approved, strain-matched, inactivated vaccines (Vaxigrip and Fluad) in non-human primates. The mRNA vaccine induced substantially stronger innate immune activation than Vaxigrip and Fluad, evidenced by rapid upregulation of genes involved in antiviral, antigen presentation and cell migration pathways, expansion of intermediate monocytes and increased secretion of pro-inflammatory cytokines. The mRNA vaccine elicited HA-specific antibodies against all four strains, with levels generally comparable to or exceeding those induced by Vaxigrip and Fluad, although this did not consistently translate to greater neutralizing capacity. Both the mRNA vaccine and Fluad generated higher frequencies of HA-specific memory B and T cell responses compared to Vaxigrip, with the mRNA vaccine inducing a particularly stronger response in the draining lymph nodes, potentially increasing antibody diversity and affinity. Altogether, these findings support the advancement of influenza mRNA vaccines as promising clinical candidates.<\/jats:p>","DOI":"10.1038\/s41541-026-01492-y","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T16:24:21Z","timestamp":1779812661000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Seasonal influenza mRNA vaccine induces stronger innate and comparable or better adaptive responses than licensed inactivated vaccines"],"prefix":"10.1038","volume":"11","author":[{"given":"Erick","family":"Berm\u00fadez-M\u00e9ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klara","family":"Lenart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Arcoverde Cerveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Engstrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrika","family":"Hellgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Cagigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Ols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Jasny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Petsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Lor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"1492_CR1","unstructured":"World Health Organization. Influenza (seasonal). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza-(seasonal). Accessed: 26 May 2025."},{"key":"1492_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14760584.2018.1407650","volume":"17","author":"V Gresset-Bourgeois","year":"2018","unstructured":"Gresset-Bourgeois, V. et al. Quadrivalent inactivated influenza vaccine (VaxigripTetraTM). Expert Rev. Vaccines 17, 1\u201311 (2018).","journal-title":"Expert Rev. Vaccines"},{"key":"1492_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3947\/ic.2013.45.2.159","volume":"45","author":"TF Tsai","year":"2013","unstructured":"Tsai, T. F. Fluad\u00ae-MF59\u00ae-Adjuvanted Influenza Vaccine in Older Adults. Infect. Chemother. 45, 159\u2013174 (2013).","journal-title":"Infect. Chemother."},{"key":"1492_CR4","first-page":"1","volume":"4","author":"F Krammer","year":"2018","unstructured":"Krammer, F. et al. Influenza. Nat. Rev. Dis. Prim. 4, 1\u201321 (2018).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1492_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41573-019-0056-x","volume":"19","author":"C-J Wei","year":"2020","unstructured":"Wei, C.-J. et al. Next-generation influenza vaccines: opportunities and challenges. Nat. Rev. Drug Discov. 19, 239\u2013252 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1492_CR6","unstructured":"CDC. CDC Seasonal Flu Vaccine Effectiveness Studies. Flu Vaccines Work https:\/\/www.cdc.gov\/flu-vaccines-work\/php\/effectiveness-studies\/index.html (2024). Accessed: 26 May 2025."},{"key":"1492_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrmicro.2017.118","volume":"16","author":"VN Petrova","year":"2018","unstructured":"Petrova, V. N. & Russell, C. A. The evolution of seasonal influenza viruses. Nat. Rev. Microbiol. 16, 47\u201360 (2018).","journal-title":"Nat. Rev. Microbiol."},{"key":"1492_CR8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41591-018-0340-z","volume":"25","author":"S Yamayoshi","year":"2019","unstructured":"Yamayoshi, S. & Kawaoka, Y. Current and future influenza vaccines. Nat. Med. 25, 212\u2013220 (2019).","journal-title":"Nat. Med."},{"key":"1492_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1146\/annurev-virology-010320-044746","volume":"7","author":"S Gouma","year":"2020","unstructured":"Gouma, S., Anderson, E. M. & Hensley, S. E. Challenges of Making Effective Influenza Vaccines. Annu. Rev. Virol. 7, 495\u2013512 (2020).","journal-title":"Annu. Rev. Virol."},{"key":"1492_CR10","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/nbt.2436","volume":"30","author":"B Petsch","year":"2012","unstructured":"Petsch, B. et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat. Biotechnol. 30, 1210\u20131216 (2012).","journal-title":"Nat. Biotechnol."},{"key":"1492_CR11","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41573-024-01042-y","volume":"23","author":"N Pardi","year":"2024","unstructured":"Pardi, N. & Krammer, F. mRNA vaccines for infectious diseases \u2014 advances, challenges and opportunities. Nat. Rev. Drug Discov. 23, 838\u2013861 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1492_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines \u2014 a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261\u2013279 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1492_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","volume":"596","author":"JS Turner","year":"2021","unstructured":"Turner, J. S. et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 596, 109\u2013113 (2021).","journal-title":"Nature"},{"key":"1492_CR14","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.cell.2022.01.018","volume":"185","author":"K R\u00f6ltgen","year":"2022","unstructured":"R\u00f6ltgen, K. et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell 185, 1025\u20131040.e14 (2022).","journal-title":"Cell"},{"key":"1492_CR15","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.ymthe.2020.04.018","volume":"28","author":"AW Freyn","year":"2020","unstructured":"Freyn, A. W. et al. A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice. Mol. Ther. 28, 1569\u20131584 (2020).","journal-title":"Mol. Ther."},{"key":"1492_CR16","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1126\/science.abm0271","volume":"378","author":"CP Arevalo","year":"2022","unstructured":"Arevalo, C. P. et al. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science 378, 899\u2013904 (2022).","journal-title":"Science"},{"key":"1492_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32149-8","volume":"13","author":"N Pardi","year":"2022","unstructured":"Pardi, N. et al. Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses. Nat. Commun. 13, 4677 (2022).","journal-title":"Nat. Commun."},{"key":"1492_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52940-z","volume":"15","author":"RA Leonard","year":"2024","unstructured":"Leonard, R. A. et al. Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA. Nat. Commun. 15, 8712 (2024).","journal-title":"Nat. Commun."},{"key":"1492_CR19","doi-asserted-by":"publisher","first-page":"2484088","DOI":"10.1080\/21645515.2025.2484088","volume":"21","author":"B Kandinov","year":"2025","unstructured":"Kandinov, B. et al. An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titers. Hum. Vaccines Immunotherapeutics 21, 2484088 (2025).","journal-title":"Hum. Vaccines Immunotherapeutics"},{"key":"1492_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.126847","volume":"50","author":"M Soens","year":"2025","unstructured":"Soens, M. et al. A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults. Vaccine 50, 126847 (2025).","journal-title":"Vaccine"},{"key":"1492_CR21","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41586-021-03791-x","volume":"596","author":"PS Arunachalam","year":"2021","unstructured":"Arunachalam, P. S. et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature 596, 410\u2013416 (2021).","journal-title":"Nature"},{"key":"1492_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39421-5","volume":"14","author":"F Hellgren","year":"2023","unstructured":"Hellgren, F. et al. Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses. Nat. Commun. 14, 3713 (2023).","journal-title":"Nat. Commun."},{"key":"1492_CR23","doi-asserted-by":"crossref","unstructured":"Odak, I. et al. Systems biology analysis reveals distinct molecular signatures associated with immune responsiveness to the BNT162b COVID-19 vaccine. eBioMedicine 99, (2024).","DOI":"10.1016\/j.ebiom.2023.104947"},{"key":"1492_CR24","doi-asserted-by":"crossref","unstructured":"Hellgren, F. et al. Modulation of innate immune response to mRNA vaccination after SARS-CoV-2 infection or sequential vaccination in humans. JCI Insight 9, (2024).","DOI":"10.1172\/jci.insight.175401"},{"key":"1492_CR25","doi-asserted-by":"crossref","unstructured":"Lindgren, G. et al. Induction of Robust B Cell Responses after Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ CXCR3+ T Follicular Helper Cells. Frontiers in Immunology 8, (2017).","DOI":"10.3389\/fimmu.2017.01539"},{"key":"1492_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal2094","volume":"9","author":"F Liang","year":"2017","unstructured":"Liang, F. et al. Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake. Sci. Transl. Med. 9, eaal2094 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1492_CR27","doi-asserted-by":"publisher","first-page":"3964","DOI":"10.1016\/j.celrep.2020.02.111","volume":"30","author":"S Ols","year":"2020","unstructured":"Ols, S. et al. Route of Vaccine Administration Alters Antigen Trafficking but Not Innate or Adaptive Immunity. Cell Rep. 30, 3964\u20133971.e7 (2020).","journal-title":"Cell Rep."},{"key":"1492_CR28","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.omtm.2022.10.001","volume":"27","author":"K Lenart","year":"2022","unstructured":"Lenart, K. et al. A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses. Mol. Ther. - Methods Clin. Dev. 27, 309\u2013323 (2022).","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"1492_CR29","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.immuni.2023.08.011","volume":"56","author":"S Ols","year":"2023","unstructured":"Ols, S. et al. Multivalent antigen display on nanoparticle immunogens increases B cell clonotype diversity and neutralization breadth to pneumoviruses. Immunity 56, 2425\u20132441.e14 (2023).","journal-title":"Immunity"},{"key":"1492_CR30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrd4529","volume":"14","author":"F Krammer","year":"2015","unstructured":"Krammer, F. & Palese, P. Advances in the development of influenza virus vaccines. Nat. Rev. Drug Discov. 14, 167\u2013182 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1492_CR31","unstructured":"World Health Organization. Global Influenza Surveillance and Response System (GISRS). https:\/\/www.who.int\/initiatives\/global-influenza-surveillance-and-response-system. Accessed: 08 July 2025."},{"key":"1492_CR32","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1038\/nm.4223","volume":"22","author":"DD Raymond","year":"2016","unstructured":"Raymond, D. D. et al. Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. Nat. Med. 22, 1465\u20131469 (2016).","journal-title":"Nat. Med."},{"key":"1492_CR33","doi-asserted-by":"publisher","first-page":"12578","DOI":"10.1073\/pnas.1712377114","volume":"114","author":"SJ Zost","year":"2017","unstructured":"Zost, S. J. et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc. Natl. Acad. Sci. 114, 12578\u201312583 (2017).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"1492_CR34","doi-asserted-by":"publisher","first-page":"e1006682","DOI":"10.1371\/journal.ppat.1006682","volume":"13","author":"NC Wu","year":"2017","unstructured":"Wu, N. C. et al. A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLOS Pathog. 13, e1006682 (2017).","journal-title":"PLOS Pathog."},{"key":"1492_CR35","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1016\/j.vaccine.2018.05.086","volume":"36","author":"TA Garretson","year":"2018","unstructured":"Garretson, T. A., Petrie, J. G., Martin, E. T., Monto, A. S. & Hensley, S. E. Identification of human vaccinees that possess antibodies targeting the egg-adapted hemagglutinin receptor binding site of an H1N1 influenza vaccine strain. Vaccine 36, 4095\u20134101 (2018).","journal-title":"Vaccine"},{"key":"1492_CR36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2206333119","volume":"119","author":"M McMahon","year":"2022","unstructured":"McMahon, M. et al. Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses. Proc. Natl. Acad. Sci. 119, e2206333119 (2022).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"1492_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39376-7","volume":"14","author":"IT Lee","year":"2023","unstructured":"Lee, I. T. et al. Safety and immunogenicity of a phase 1\/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis. Nat. Commun. 14, 3631 (2023).","journal-title":"Nat. Commun."},{"key":"1492_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00980-3","volume":"9","author":"T Hauguel","year":"2024","unstructured":"Hauguel, T. et al. Preclinical immunogenicity and safety of hemagglutinin-encoding modRNA influenza vaccines. npj Vaccines 9, 183 (2024).","journal-title":"npj Vaccines"},{"key":"1492_CR39","doi-asserted-by":"crossref","unstructured":"Fierro, C. et al. Shared clinical and immunologic features of mRNA vaccines: preliminary results from a comparative clinical study. Frontiers in Immunology 16, (2025).","DOI":"10.3389\/fimmu.2025.1501275"},{"key":"1492_CR40","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1074-7613(01)00126-1","volume":"14","author":"A Le Bon","year":"2001","unstructured":"Le Bon, A. et al. Type I Interferons Potently Enhance Humoral Immunity and Can Promote Isotype Switching by Stimulating Dendritic Cells In Vivo. Immunity 14, 461\u2013470 (2001).","journal-title":"Immunity"},{"key":"1492_CR41","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1189\/jlb.0810460","volume":"89","author":"C Gujer","year":"2011","unstructured":"Gujer, C. et al. IFN-\u03b1 produced by human plasmacytoid dendritic cells enhances T cell-dependent na\u00efve B cell differentiation. J. Leukoc. Biol. 89, 811\u2013821 (2011).","journal-title":"J. Leukoc. Biol."},{"key":"1492_CR42","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nri.2017.28","volume":"17","author":"CV Jakubzick","year":"2017","unstructured":"Jakubzick, C. V., Randolph, G. J. & Henson, P. M. Monocyte differentiation and antigen-presenting functions. Nat. Rev. Immunol. 17, 349\u2013362 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"1492_CR43","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.chom.2014.06.001","volume":"16","author":"M Kwissa","year":"2014","unstructured":"Kwissa, M. et al. Dengue Virus Infection Induces Expansion of a CD14+CD16+ Monocyte Population that Stimulates Plasmablast Differentiation. Cell Host Microbe 16, 115\u2013127 (2014).","journal-title":"Cell Host Microbe"},{"key":"1492_CR44","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41684-025-01547-y","volume":"54","author":"X Yan","year":"2025","unstructured":"Yan, X. et al. Biochemical and hematological reference intervals in rhesus and cynomolgus macaques and implications for vaccine and drug development. Lab Anim. 54, 141\u2013155 (2025).","journal-title":"Lab Anim."},{"key":"1492_CR45","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1492_CR46","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","volume":"383","author":"EJ Anderson","year":"2020","unstructured":"Anderson, E. J. et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N. Engl. J. Med. 383, 2427\u20132438 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1492_CR47","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1492_CR48","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1093\/cid\/ciac319","volume":"75","author":"J Kim","year":"2022","unstructured":"Kim, J. et al. Effectiveness of Booster mRNA Vaccines Against SARS-CoV-2 Infection in an Elderly Population, South Korea, October 2021\u2013January 2022. Clin. Infect. Dis. 75, 920\u2013921 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"1492_CR49","doi-asserted-by":"publisher","first-page":"e585","DOI":"10.1093\/cid\/ciac169","volume":"75","author":"B Speich","year":"2022","unstructured":"Speich, B. et al. Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial. Clin. Infect. Dis. 75, e585\u2013e593 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"1492_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105385","volume":"109","author":"P Chen","year":"2024","unstructured":"Chen, P. et al. Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID. eBioMedicine 109, 105385 (2024).","journal-title":"eBioMedicine"},{"key":"1492_CR51","doi-asserted-by":"crossref","unstructured":"Hassett, K. J. et al. mRNA vaccine trafficking and resulting protein expression after intramuscular administration. Molecular Therapy Nucleic Acids 35, (2024).","DOI":"10.1016\/j.omtn.2023.102083"},{"key":"1492_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57446-w","volume":"16","author":"GS Blizard","year":"2025","unstructured":"Blizard, G. S. et al. Monitoring mRNA vaccine antigen expression in vivo using PET\/CT. Nat. Commun. 16, 2234 (2025).","journal-title":"Nat. Commun."},{"key":"1492_CR53","doi-asserted-by":"crossref","unstructured":"Zens, K. D., Chen, J. K. & Farber, D. L. Vaccine-generated lung tissue\u2013resident memory T cells provide heterosubtypic protection to influenza infection. JCI Insight 1, (2016).","DOI":"10.1172\/jci.insight.85832"},{"key":"1492_CR54","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abb6852","volume":"6","author":"YM Son","year":"2021","unstructured":"Son, Y. M. et al. Tissue-resident CD4+ T helper cells assist the development of protective respiratory B and CD8+ T cell memory responses. Sci. Immunol. 6, eabb6852 (2021).","journal-title":"Sci. Immunol."},{"key":"1492_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54620-4","volume":"15","author":"KH Ko","year":"2024","unstructured":"Ko, K. H. et al. A vaccine platform targeting lung-resident memory CD4+ T-cells provides protection against heterosubtypic influenza infections in mice and ferrets. Nat. Commun. 15, 10368 (2024).","journal-title":"Nat. Commun."},{"key":"1492_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37162-z","volume":"14","author":"ML Myers","year":"2023","unstructured":"Myers, M. L. et al. Commercial influenza vaccines vary in HA-complex structure and in induction of cross-reactive HA antibodies. Nat. Commun. 14, 1763 (2023).","journal-title":"Nat. Commun."},{"key":"1492_CR57","doi-asserted-by":"crossref","unstructured":"Waldock, J. et al. Haemagglutination inhibition and virus microneutralisation serology assays: use of harmonised protocols and biological standards in seasonal influenza serology testing and their impact on inter-laboratory variation and assay correlation: A FLUCOP collaborative study. Frontiers in Immunology 14, (2023).","DOI":"10.3389\/fimmu.2023.1155552"},{"key":"1492_CR58","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.omtm.2022.09.013","volume":"27","author":"C Chang","year":"2022","unstructured":"Chang, C. et al. Self-amplifying mRNA bicistronic influenza vaccines raise cross-reactive immune responses in mice and prevent infection in ferrets. Mol. Ther. Methods Clin. Dev. 27, 195\u2013205 (2022).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1492_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60938-4","volume":"16","author":"AK Rudman Spergel","year":"2025","unstructured":"Rudman Spergel, A. K. et al. Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidase. Nat. Commun. 16, 5933 (2025).","journal-title":"Nat. Commun."},{"key":"1492_CR60","doi-asserted-by":"crossref","unstructured":"Wang, T. et al. Improved cross-protection and immunity against influenza A virus in mice using a novel mRNA vaccine with optimized design of RNA sequence. Molecular Therapy Nucleic Acids 37, (2026).","DOI":"10.1016\/j.omtn.2025.102787"},{"key":"1492_CR61","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","volume":"16","author":"K Karik\u00f3","year":"2008","unstructured":"Karik\u00f3, K. et al. Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability. Mol. Ther. 16, 1833\u20131840 (2008).","journal-title":"Mol. Ther."},{"key":"1492_CR62","doi-asserted-by":"crossref","unstructured":"Engstrand, O. et al. Immunogenicity and innate immunity to high-dose and repeated vaccination of modified mRNA versus unmodified mRNA. Molecular Therapy Nucleic Acids 36, (2025).","DOI":"10.1016\/j.omtn.2025.102588"},{"key":"1492_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-017-0032-6","volume":"2","author":"J Lutz","year":"2017","unstructured":"Lutz, J. et al. Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. npj Vaccines 2, 29 (2017).","journal-title":"npj Vaccines"},{"key":"1492_CR64","unstructured":"Kassambara, A. & Mundt, F. factoextra: Extract and visualize the results of multivariate data analyses. R package version 2.0.0. https:\/\/CRAN.R-project.org\/package=factoextra (2020)."},{"key":"1492_CR65","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"1492_CR66","doi-asserted-by":"publisher","first-page":"9440","DOI":"10.1073\/pnas.1530509100","volume":"100","author":"JD Storey","year":"2003","unstructured":"Storey, J. D. & Tibshirani, R. Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. 100, 9440\u20139445 (2003).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"1492_CR67","unstructured":"Storey, J. D., Bass, A. J., Dabney, A., Robinson, D. & Warnes, G. qvalue: Q-value estimation for false discovery rate control. R package version 2.42.0. https:\/\/bioconductor.org\/packages\/qvalue (2025)."},{"key":"1492_CR68","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/ni.2789","volume":"15","author":"S Li","year":"2014","unstructured":"Li, S. et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat. Immunol. 15, 195\u2013204 (2014).","journal-title":"Nat. Immunol."},{"key":"1492_CR69","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L.-G., Han, Y. & He, Q.-Y. clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters. OMICS: A J. Integr. Biol. 16, 284\u2013287 (2012).","journal-title":"OMICS: A J. Integr. Biol."},{"key":"1492_CR70","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu, T. et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation 2, 100141 (2021).","journal-title":"Innovation"},{"key":"1492_CR71","doi-asserted-by":"crossref","unstructured":"Thompson, E. A. et al. TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25. JCI Insight 3, (2018).","DOI":"10.1172\/jci.insight.120692"},{"key":"1492_CR72","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria. https:\/\/www.R-project.org\/ (2021)."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01492-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01492-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01492-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T18:02:51Z","timestamp":1779818571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01492-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1492"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01492-y","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.J. and B.P. are current or former employees of CureVac SE, a company developing mRNA based vaccines and immunotherapeutics, which developed the influenza mRNA vaccine evaluated in this study. All other authors declare no competing financial or non-financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"108"}}